脊髓电刺激治疗疼痛随机对照试验的脆弱指数评估
该研究通过脆弱指数评估脊髓电刺激(SCS)治疗慢性疼痛的随机对照试验(RCT)的统计稳健性。共纳入30项RCT,主要结局的中位脆弱指数为5.45(IQR 3.00–11.45),不同结局类型、原发与继发疼痛结局及利益冲突与否间无统计学差异(P分别为0.710、0.771、0.753)。结论认为多数RCT的疼痛结局较为稳健。
要点
- SCS治疗慢性疼痛的RCT中位脆弱指数为5.45,提示结局整体较稳健。
- 原发与继发疼痛结局、二分类与连续结局的脆弱指数无显著差异。
- 利益冲突存在与否未影响试验脆弱性(P=0.753)。
核心结论
- 多数评估SCS治疗原发性疼痛结局的RCT具有相对较高的脆弱指数,结论较为稳健。
研究设计与样本
- 系统检索评估SCS用于任何慢性疼痛适应症的RCT,共纳入30项RCT。
- 主要结局为试验特异性脆弱指数(针对预设疼痛主要结局)。
主要发现
- 所有试验主要结局的中位脆弱指数为5.45(IQR 3.00–11.45)。
- 二分类与连续结局的脆弱指数无统计学差异(P=0.710)。
- 原发与继发疼痛结局的脆弱指数无统计学差异(P=0.771)。
- 有无利益冲突的试验脆弱指数无统计学差异(P=0.753)。
- 中位脆弱指数大于3的适应症包括持续脊柱疼痛综合征2型8.00(2.80–12.60)、痛性糖尿病神经病变6.00(3.00–11.80)、复杂区域疼痛综合征7.20(4.62–81.50)、混合病因9.00(3.00–38.00)及其他病因3.00(1.00–8.55)。
临床怎么用
- 报告试验脆弱指数可帮助临床医生更全面评估RCT稳健性并辅助治疗决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The use of spinal cord stimulation (SCS) for managing severe refractory chronic pain has expanded considerably due to positive statistical evidence regarding its use; however, the statistical robustness of the underlying randomized controlled trials (RCTs) requires further scrutiny. One such tool that can be used for this purpose is the fragility index, which quantifies how many individual outcome events must be altered for an outcome to lose statistical significance. Thus the index can be used quantitatively to assess the stability and robustness of an RCT's conclusions, with higher values indicating increased trial stability. This study assesses the fragility of pain outcomes across RCTs investigating SCS for chronic pain to better understand the quality and robustness of evidence. METHODS: A systematic search was conducted for RCTs assessing SCS for any chronic pain indication. The primary outcome was an evaluation of the trial-specific fragility index for the prespecified pain primary outcomes of RCTs. Secondary outcomes included an evaluation of fragility for (1) specified indications for SCS therapy, (2) reported pain outcomes appearing in three or more RCTs, (3) the presence/absence of a conflict of interest, and (4) comparisons of SCS to conservative management or different SCS waveform modalities. RESULTS: A total of 30 RCTs were included. The median (interquartile range [IQR]) fragility index across the primary outcome of all trials was 5.45 (3.00 to 11.45). There was no statistical difference between the (1) types of outcomes (dichotomous vs. continuous; P = 0.710), (2) primary versus secondary pain outcomes ( P = 0.771), or (3) presence versus absence of trial conflict of interest ( P = 0.753). Indications with a median (IQR) fragility score greater than three included persistent spinal pain syndrome type 2 with a score of 8.00 (2.80 to 12.60), painful diabetic neuropathy with a score of 6.00 (3.00 to 11.80), complex regional pain syndrome with a score of 7.20 (4.62 to 81.50), mixed etiologies with a score of 9.00 (3.00 to 38.00), and other etiologies with a score of 3.00 (1.00 to 8.55). CONCLUSIONS: This study suggests that the majority of RCTs investigating primary pain outcomes after SCS therapy are robust with relatively high fragility scores. Reporting the fragility of outcomes in trials can provide a more comprehensive assessment of trial robustness and can further aid clinicians in interpreting trial results and making informed treatment decisions.
引用
- Hussain N, Brull R, Shah R, et al. Evaluating the Statistical Robustness of Randomized Controlled Trials of Spinal Cord Stimulation for Pain through the Use of Fragility Index. Anesthesiology. 2025. PMID: 41376548. doi:10.1097/ALN.0000000000005876
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。